Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $43.20 Average PT from Analysts

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has earned an average rating of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $45.6667.

A number of research firms have weighed in on RIGL. Citigroup reissued a “buy” rating on shares of Rigel Pharmaceuticals in a report on Wednesday, January 14th. Zacks Research upgraded shares of Rigel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 18th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, December 21st.

Rigel Pharmaceuticals Price Performance

Shares of NASDAQ RIGL opened at $28.87 on Wednesday. The stock’s 50-day simple moving average is $36.85 and its 200-day simple moving average is $37.20. The firm has a market capitalization of $533.32 million, a PE ratio of 1.53 and a beta of 1.10. Rigel Pharmaceuticals has a fifty-two week low of $15.50 and a fifty-two week high of $52.24. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.30 and a current ratio of 2.42.

Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported $1.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.33 by ($0.19). The business had revenue of $69.80 million during the quarter, compared to analyst estimates of $68.70 million. Rigel Pharmaceuticals had a net margin of 124.72% and a return on equity of 79.84%. As a group, equities research analysts forecast that Rigel Pharmaceuticals will post 0.22 EPS for the current fiscal year.

Insider Activity

In other Rigel Pharmaceuticals news, Director Walter H. Moos sold 4,000 shares of the firm’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $36.36, for a total transaction of $145,440.00. Following the transaction, the director owned 12,722 shares of the company’s stock, valued at approximately $462,571.92. This trade represents a 23.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 9.48% of the company’s stock.

Institutional Trading of Rigel Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. AlphaQuest LLC increased its position in Rigel Pharmaceuticals by 234.8% during the third quarter. AlphaQuest LLC now owns 1,105 shares of the biotechnology company’s stock worth $31,000 after buying an additional 775 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in Rigel Pharmaceuticals by 400.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,275 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 1,020 shares during the last quarter. IFP Advisors Inc acquired a new stake in shares of Rigel Pharmaceuticals in the third quarter valued at approximately $55,000. CWM LLC boosted its holdings in shares of Rigel Pharmaceuticals by 217.0% in the fourth quarter. CWM LLC now owns 1,791 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 1,226 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Rigel Pharmaceuticals during the third quarter worth approximately $62,000. 66.23% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Rigel Pharmaceuticals

Here are the key news stories impacting Rigel Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright sharply raised its FY2026 EPS forecast to $4.73 from $3.14, signaling much stronger near-term profitability expectations that could support higher valuation if realized.
• Neutral Sentiment: HC Wainwright published detailed quarterly 2026 forecasts (Q1: $0.95, Q2: $1.20, Q3: $1.27, Q4: $1.30) that provide a clear earnings cadence for the year but reflect forward modeling assumptions investors should verify against company guidance and pipeline progress.
• Neutral Sentiment: The company’s recent earnings call transcript offers management commentary and operational detail investors should review to reconcile analyst projections with product, revenue and margin drivers. Rigel Pharma (RIGL) Earnings Call Transcript
• Negative Sentiment: Rigel disclosed significant uncertainty around pursuing FDA fast-track designation for its programs, which raises regulatory execution risk that could delay approvals or returns and pressure the stock. Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).